drugset / Trial / NCT04910178
Follow-up of NAFLD Patients With MRI-PDFF
RandomizedParallel-groupSingle-blindTreatment
Summary
The liver is a key organ in metabolism and contributes to T2DM development and insulin resistance via unclear mechanisms that may involve liver fat accumulation, inflammatory signals, and immune cells are proposed to play an important role in the pathogenesis of both NAFLD and T2DM.
Timeline
- Start
- 2020-12-01
- Primary completion
- 2021-12-01
- Completion
- 2021-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Empagliflozin | Small molecule | 25 mg | Oral |
| Subject | Pentoxifylline | Small molecule | 400 mg | Oral |
| Subject | Ursodeoxycholic Acid | Small molecule | 500 mg | Oral |